skip to main content

MS – DMT De-Escalation Factors — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMultiple Sclerosis & CNS InflammationMS – DMT De-Escalation FactorsSCE Neurology

A 55-year-old woman with MS has been on interferon beta-1a for 5 years. She has had no relapses and no new MRI lesions. She is concerned about continuing injections indefinitely. She asks about treatment de-escalation. What factors should be considered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — De-escalation may be considered in clinically and radiologically stable patients — factors include: age >50, stable EDSS for ≥5 years, no relapses for ≥5 years, no MRI activity for ≥5 years, and patient preference — but the decision must balance relapse risk against treatment burden

DMT de-escalation (stepping down to a lower-efficacy DMT or stopping) is an evolving area in MS. It may be considered in selected patients with long-term disease stability, particularly older patients where the inflammatory component of MS naturally diminishes. Factors favouring de-escalation: age >50 (lower relapse risk), prolonged stability (≥5 years no relapses, no MRI activity, stable EDSS), patient preference (injection fatigue, side effects). Risks: potential for relapse (especially if on high-efficacy DMTs with rebound potential like natalizumab or fingolimod). Close MRI monitoring after de-escalation is essential. A: Lifelong therapy is not always necessary. C: Can be appropriate in selected patients. D: Abrupt cessation can cause rebound. E: Shared decision-making is essential.

Reference: ABN MS Guidelines (2022); Kister et al. Treatment De-Escalation